DAAN GENE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.1 CNY | +0.42% |
|
-1.11% | -26.65% |
| Apr. 29 | Daan Gene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 26 | Daan Gene Gets Nod to Register Detection Kit for Influenza Viruses, COVID-19 | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 8,102 | 9,170 | 30,086 | 28,153 | 21,838 | 13,585 |
| Enterprise Value (EV) 1 | 8,826 | 9,981 | 28,740 | 25,998 | 18,505 | 11,552 |
| P/E ratio | 78.1 x | 99.5 x | 12.3 x | 7.78 x | 4.03 x | 130 x |
| Yield | 0.4% | 0.22% | 1.6% | 5.53% | 11.2% | 0.15% |
| Capitalization / Revenue | 5.48 x | 8.35 x | 5.63 x | 3.67 x | 1.81 x | 11.5 x |
| EV / Revenue | 5.97 x | 9.09 x | 5.38 x | 3.39 x | 1.54 x | 9.78 x |
| EV / EBITDA | 53.4 x | -1,040 x | 11.1 x | 6.44 x | 2.88 x | -939 x |
| EV / FCF | 85.9 x | 59.4 x | 19.8 x | 15.6 x | 12.3 x | 26.6 x |
| FCF Yield | 1.16% | 1.68% | 5.05% | 6.4% | 8.12% | 3.76% |
| Price to Book | 4.46 x | 4.98 x | 7.05 x | 3.83 x | 1.93 x | 1.53 x |
| Nbr of stocks (in thousands) | 1,403,446 | 1,403,446 | 1,403,446 | 1,403,446 | 1,403,446 | 1,403,446 |
| Reference price 2 | 5.773 | 6.534 | 21.44 | 20.06 | 15.56 | 9.680 |
| Announcement Date | 3/29/19 | 4/29/20 | 3/30/21 | 3/30/22 | 3/30/23 | 3/29/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,479 | 1,098 | 5,341 | 7,664 | 12,046 | 1,181 |
| EBITDA 1 | 165.2 | -9.597 | 2,580 | 4,037 | 6,418 | -12.3 |
| EBIT 1 | 79.02 | -83.55 | 2,509 | 3,901 | 6,156 | -354.1 |
| Operating Margin | 5.34% | -7.61% | 46.97% | 50.9% | 51.1% | -29.99% |
| Earnings before Tax (EBT) 1 | 101.9 | 6.053 | 2,903 | 4,120 | 6,319 | 113.5 |
| Net income 1 | 101.6 | 92.18 | 2,449 | 3,618 | 5,412 | 104.7 |
| Net margin | 6.87% | 8.39% | 45.85% | 47.21% | 44.93% | 8.86% |
| EPS 2 | 0.0739 | 0.0657 | 1.745 | 2.578 | 3.856 | 0.0746 |
| Free Cash Flow 1 | 102.8 | 167.9 | 1,451 | 1,665 | 1,502 | 434.1 |
| FCF margin | 6.95% | 15.29% | 27.17% | 21.72% | 12.47% | 36.76% |
| FCF Conversion (EBITDA) | 62.25% | - | 56.25% | 41.24% | 23.4% | - |
| FCF Conversion (Net income) | 101.2% | 182.19% | 59.25% | 46.01% | 27.75% | 414.8% |
| Dividend per Share 2 | 0.0233 | 0.0142 | 0.3438 | 1.110 | 1.750 | 0.0150 |
| Announcement Date | 3/29/19 | 4/29/20 | 3/30/21 | 3/30/22 | 3/30/23 | 3/29/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 724 | 811 | - | - | - | - |
| Net Cash position 1 | - | - | 1,347 | 2,155 | 3,333 | 2,034 |
| Leverage (Debt/EBITDA) | 4.386 x | -84.48 x | - | - | - | - |
| Free Cash Flow 1 | 103 | 168 | 1,451 | 1,665 | 1,502 | 434 |
| ROE (net income / shareholders' equity) | 3.58% | -2.2% | 74.2% | 59.4% | 56.3% | 0.69% |
| ROA (Net income/ Total Assets) | 1.19% | -1.45% | 30.6% | 28.6% | 30.7% | -1.72% |
| Assets 1 | 8,541 | -6,377 | 8,015 | 12,640 | 17,651 | -6,094 |
| Book Value Per Share 2 | 1.290 | 1.310 | 3.040 | 5.240 | 8.050 | 6.330 |
| Cash Flow per Share 2 | 0.2700 | 0.1600 | 0.6200 | 1.550 | 1.850 | 0.7100 |
| Capex 1 | 100 | 93.3 | 365 | 659 | 1,503 | 573 |
| Capex / Sales | 6.79% | 8.5% | 6.83% | 8.6% | 12.47% | 48.5% |
| Announcement Date | 3/29/19 | 4/29/20 | 3/30/21 | 3/30/22 | 3/30/23 | 3/29/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -26.65% | 1.37B | |
| -20.79% | 56.08M |
- Stock Market
- Equities
- 002030 Stock
- Financials Daan Gene Co., Ltd.
